Current status of imaging infections with radiolabeled anti-infective agents

Anti-Infective Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2009, Pages 272-287

  Welling, Mick M ^a   Ferro Flores, Guillermina ^b   Pirmettis, Ioannis ^c   Brouwer, Carlo P J M ^a,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d TNO   (Netherlands)

Author keywords

Antibiotics; Antimicrobial peptides; Infection; Radiolabeling; Scintigraphy; Technetium

Indexed keywords

ANTIINFECTIVE AGENT; CEFOPERAZONE; CEFTIZOXIME; CHITINASE; CIPROFLOXACIN; ENROFLOXACIN; ERYTHROMYCIN; FIALURIDINE; FLUCONAZOLE; FLUORINE 18; GANCICLOVIR; INFECTON; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; NORFLOXACIN; OFLOXACIN; ORNIDAZOLE; PEFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADIOPHARMACEUTICAL AGENT; SPARFLOXACIN; STREPTOMYCIN; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG STRUCTURE; HUMAN; INFECTION; INFLAMMATION; ISOTOPE LABELING; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POLYMERIZATION; POSITRON EMISSION TOMOGRAPHY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; STRUCTURE ANALYSIS;

EID: 70249148605     PISSN: 18715214     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152109788680180     Document Type: Article

References (102)

1. Palestro, C.J.; Love, C.; Miller, T.T. Diagnostic Imaging tests and microbial infections. Cell. Microbiol., 2007, 9, 2323-2333.
2. Becker, W. The contribution of nuclear-medicine to the patient with infection. Eur. J. Nucl. Med. Mol., 1995, 22, 1195-1211.
3. Weiner, R.E.; Thakur, M.L. Imaging infection/inflammations - Pathophysiologic basis and radiopharmaceuticals. Q. J. Nucl. Med., 1999, 43, 2-8.
4. Becker, W.; Meller, J. The role of nuclear medicine in infection and inflammation. Lancet Infect. Dis., 2001, 1, 326-333.
5. Calame, W.; Welling, M.; Feitsma, H.I.J.; Ensing, G.J.; Pauwels, E.K.J. Improved detection of a staphylococcal infection by monomeric and protein a-purified polyclonal human-immunoglobulin. Eur. J. Nucl. Med. Mol. I., 1993, 20, 490-494.
6. Welling, M.; Feitsma, H.I.J.; Calame, W.; Ensing, G.J.; Goedemans, W.; Pauwels, E.K.J. Optimized localization of bacterial-infections with Tc-99m labeled human-immunoglobulin after protein charge selection. Eur. J. Nucl. Med. Mol. I., 1994, 21, 1135-1140.
7. Welling, M.; Feitsma, H.I.J.; Calame, W.; Pauwels, E.K.J. Localization of a bacterial infection with Tc-99(m)-labelled human IgG: Further improvement with enriched IgG subclass preparations. Nucl. Med. Commun., 1997, 18, 1057-1064.
8. Hazra, D.K.; Britton, K.E.; Lahiri, V.L.; Gupta, A.K.; Khanna, P.; Saran, S. Immunotechnological trends in radioimmunotargeting - from magic bullet to smart bomb. Nucl. Med. Commun., 1995, 16, 66-75.
9. Becker, W.; Palestro, C.J.; Winship, J.; Feld, T.; Pinsky, C.M.; Wolf, F.; Goldenberg, D.M. Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan). Clin. Orthop. Relat. Res., 1996, 263-272.
10. Welling, M.; Feitsma, H.I.J.; Calame, W.; Pauwels, E.K.J. Detection of experimental infections with Tc-99m-labeled monoclonal antibodies against TNF-alpha and interleukin-8. Nucl. Med. Biol., 1997, 24, 649-655.
11. Rao, P.S.; Pallela, V.R.; Vassileva-Belnikolovska, D.; Jungkind, D.; Thakur, M.L. A receptor-specific peptide for imaging infection and inflammation. Nucl. Med. Commun., 2000, 21, 1063-1070.
12. Boerman, O.C.; Dams, E.T.M.; Oyen, W.J.G.; Corstens, F.H.M.; Storm, G. Radiopharmaceuticals for scintigraphic imaging of infection and inflammation. Inflam. Res., 2001, 50, 55-64.
13. Signore, A.; Chianelli, M.; Bei, R.; Oyen, W.; Modesti, A. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine (vol 30, pg 149, 2003). Eur. J. Nucl. Med. Mol. I., 2003, 30, 801-802.
14. Nibbering, P.H.; Welling, M.M.; Van den Broek, P.J.; Van Wyngaarden, K.E.; Pauwels, E.K.J.; Calame, W. Radiolabelled antimicrobial peptides for imaging of infections: A review. Nucl. Med. Commun., 1998, 19, 1117-1121.
15. Prokesch, R.C.; Hand, W.L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob. Agents. Chemother., 1982, 21, 373-380.
16. Fischman, A.J.; Alpert, N.M.; Livni, E.; Ray, S.; Sinclair, I.; Elmaleh, D.R.; Weiss, S.; Correia, J.A.; Webb, D.; Liss, R.; Strauss, H.W.; Rubin, R.H. Pharmacokinetics of F-18 labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. J. Pharmacol. Exp. Ther., 1991, 259, 1351-1359.
17. Tewson, T.J. Labeled antibiotics: Positron tomography as a tool for measuring tissue distribution. Drug Dev. Res., 2003, 59, 261-268.
18. Langer, O.; Mitterhauser, M.; Wadsak, W.; Brunner, M.; Muller, U.; Kletter, K.; Muller, M. A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. J. Labelled Comp. Radiopharm., 2003, 46, 715-727.
19. Dewanjee, M.K. The chemistry of 99mTc-labeled radiopharmaceuticals. Semin. Nucl. Med., 1990, 20, 5-27.
20. Ercan, M.T.; Aras, T.; Unsal, I.S. Evaluation of Tc-99M-Erythromycin and Tc-99M-Streptomycin Sulfate for the Visualization of Inflammatory Lesions. Nucl. Med. Biol., 1992, 19, 803-806.
21. Benitez, A.; Roca, M.; Martin-Comin, J. Labeling of antibiotics for infection diagnosis. Q. J. Nucl. Med. Mol. Imaging, 2006, 50, 147-152.
22. Gomes, B., V; Rabiller, G.; Iglesias, F.; Soroa, V.; Tubau, F.; Roca, M.; Martin-Comin, J. 99mTc-ceftizoxime scintigraphy in normal rats and abscess induced rats. Rev. Esp. Med. Nucl., 2005, 24, 312-318.
23. Motaleb, M.A. Preparation of Tc-99m-cefoperazone complex, a novel agent for detecting sites of infection. J. Radioanal. Nucl. Chem., 2007, 272, 167-171.
24. Das, S.S.; Hall, A.V.; Wareham, D.W.; Britton, K.E. Infection imaging with radiopharmaceuticals in the 21(st) century. Braz. Arch. Biol. Technol., 2002, 45, 25-37.
25. Muller, M.; Pena, A.D.; Derendorf, H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Distribution in tissue. Antimicrob. Agents. Chemother., 2004, 48, 1441-1453.
26. Siaens, R.H.; Rennen, H.J.; Boerman, O.C.; Dierckx, R.; Slegers, G. Synthesis and comparison of Tc-99m-enrofloxacin and Tc-99m-ciprofloxacin. J. Nucl. Med., 2004, 45, 2088-2094.
27. El Ghany, E.A.; Amin, A.M.; El Kawy, O.A.; Amin, M. Technetium-99m labeling and freeze-dried kit formulation of levofloxacin (L-Flox): A novel agent for detecting sites of infection. J. Labelled Comp. Radiopharm., 2007, 50, 25-31.
28. Motaleb, M.A. Preparation and biodistribution of Tc-99m-lomefloxacin and Tc-99m-ofloxacin complexes. J. Radioanal. Nucl. Chem., 2007, 272, 95-99.
29. Singh, AK.; Verma, J.; Bhatnagar, A.; Ali, A. Tc-99m-labelled sparfloxacin: a specific infection imaging agent. World. J. Nucl. Med., 2003, 2, 103-109.
30. Oh, S.J.; Ryu, J.S.; Shin, J.W.; Yoon, E.J.; Ha, H.J.; Cheon, J.H.; Lee, H.K. Synthesis of 99mTc-ciprofloxacin by different methods and its biodistribution. Appl. Radiat. Isotop., 2002, 57, 193-200.
31. Rodriguez-Puig, D.; Piera, C.; Fuster, D.; Soriano, A.; Sierra, J.M.; Rubi, S.; Suades, J. A new method of [Tc-99m]-ciprofloxacin preparation and quality control. J. Labelled Comp. Radiopharm., 2006, 49, 1171-1176.
32. Welling, M.M.; Nibbering, P.H.; Paulusma-Annema, A.; Hiemstra, P.S.; Pauwels, E.K.J.; Calame, W. Imaging of bacterial infections with Tc-99m-labeled human neutrophil peptide-1 - Reply. J. Nucl. Med., 2000, 41, 2100-2102.
33. Sarda, L.; Saleh-Mghir, A.; Peker, C.; Meulemans, A.; Cremieux, A.C.; Le Guludec, D. Evaluation of Tc-99m-ciprofloxacin scintigraphy in a rabbit model of Staphylococcus aureus prosthetic joint infection. J. Nucl. Med., 2002, 43, 239-245.
34. Dumarey, N.; Blocklet, D.; Appelboom, T.; Tant, L.; Schoutens, A. Infecton is not specific for bacterial osteo-articular infective pathology. Eur. J. Nucl. Med. Mol. I., 2002, 29, 530-535.
35. Sarda, L.; Cremieux, A.C.; Lebellec, Y.; Meulemans, A.; Lebtahi, R.; Hayem, G.; Genin, R.; Delahaye, N.; Huten, D.; Le Guludec, D. Inability of Tc-99m-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J. Nucl. Med., 2003, 44, 920-926.
36. Welling, M.; Stokkel, M.; Balter, J.; Sarda-Mantel, L.; Meulemans, A.; Le Guludec, D. The many roads to infection imaging. Eur. J. Nucl. Med. Mol. I., 2008, 35, 848-849.
37. Palestro C.J.; Love, C.; Caprioli, R.; Marwin, S.E.; Richardson, H.; Haight, J.; Tronco, G.G.; Pugliese, P.V.; Bhargava KK: Phase II study of 99mTc-ciprofloxacin uptake in patients with high suspicion of osteomyelitis [abstract]. J. Nucl. Med. 2007, 47, 152.
38. http://www.draxishealth.com/pdf/Draxis_Q3_PR_US_GAAP.pdf.
39. Langer, O.; Brunner, M.; Zeitlinger, M.; Ziegler, S.; Muller, U.; Dobrozemsky, G.; Lackner, E.; Joukhadar, C.; Mitterhauser, M.; Wadsak, W.; Minar, E.; Dudczak, R.; Kletter, K.; Muller, M. In vitro and in vivo evaluation of [F-18]ciprofloxacin for the imaging of bacterial infections with PET. Eur. J. Nucl. Med. Mol. I., 2005, 32, 143-150.
40. Zijlstra, S.; Gunawan, J.; Freytag, C.; Burchert, W. Synthesis and evaluation of fluorine-18 labelled compounds for imaging of bacterial infections with pet. Appl. Radiat. Isotop., 2006, 64, 802-807.
41. El Ghany, E.A.; El Kolaly, M.T.; Amine, A.M.; El Sayed, A.S.; Abdel-Gelil, F. Synthesis of Tc-99m-pefloxacin: A new targeting agent for infectious foci. J. Radioanal. Nucl. Chem., 2005, 266, 131-139.
42. Pirmettis, L.; Limouris, G.S.; Papadopoulos, M.; Chiotellis, E. Potential infection imaging agents: Preparation and biodistribution of Tc-99m-norfloxacin and Tc99m-ciprofloxacin. Eur. J. Nucl. Med. Mol. I., 1999, 26, 1108.
43. Gemmel, F.; Dumarey, N.; Palestro, C.J. Radionuclide imaging of spinal infections. Eur. J. Nucl. Med. Mol. I., 2006, 33, 1226-1237.
44. Roohi, S.; Mushtaq, A.; Jehangir, M.; Malik, S.A. Synthesis, quality control and biodistribution of Tc-99m-Kanamycin. J. Radioanal. Nucl. Chem., 2006, 267, 561-566.
45. Singh, AK.; Verma, I.; Bhatnagar, A.; Sen, S.; Bose, M. Tc-99m Isoniazid: A specific agent for diagnosis of tuberculosis. World J. Nucl. Med., 2003, 2, 292-305.
46. Roohi, S.; Mushtaq, A.; Jehangir, M.; Malik, S.A. Direct labeling of isoniazid with technetium-99m for diagnosis of tuberculosis. Radiochim. Acta, 2006, 94, 147-152.
47. Lupetti, A.; Welling, M.M.; Mazzi, U.; Nibbering, P.H.; Pauwels, E.K.J. Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. Eur. J. Nucl. Med. Mol. I., 2002, 29, 674-679.
48. Bettegowda, C.; Foss, C.A.; Cheong, I.; Wang, Y.; Diaz, L.; Agrawal, N.; Fox, J.; Dick, J.; Dang, L.H.; Zhou, S.; Kinzler, K.W.; Vogelstein, B.; Pomper, M.G. From the Cover: Imaging bacterial infections with radiolabeled 1-(2′-deoxy-2′-fluoro- {beta}-D-arabinofuranosyl)-5- iodouracil. Proc. Natl. Acad. Sci. USA, 2005, 102, 1145-1150.
49. Asikoglu, M.; Yurt, F.; Cagliyan, O.; Unak, P.; Ozkilic, H. Detecting inflammation with I-131-labeled ornidazole. Appl. Radiat. Isotop., 2000, 53, 411-413.
50. Rossouw, D.D.; Lotter, M.G.; du Raan, H.; Jansen, S.E.; Hohn, A.; Burger, B.V. Radiosynthesis and evaluation of two novel I-123-labeled 2-methyl-4-nitroimidazole derivatives as potential infection imaging agents. Nucl. Med. Biol., 2005, 32, 385-394.
51. Welling, M.M.; Paulusma-Annema, A.; Balter, H.S.; Pauwels, E.K.J.; Nibbering, P.H. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur. J. Nucl. Med. Mol. I., 2000, 27, 292-301.
52. Mcphee, J.B.; Hancock, R.E.W. Function and therapeutic potential of host defence peptides. J. Pept. Sci., 2005, 11, 677-687.
53. Hancock, R.E.W.; Scott, M.G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. USA, 2000, 97,55.
54. Hancock, R.E.W. Peptide antibiotics. Lancet., 1997, 349, 418-422.
55. Otvos, L. Antibacterial peptides and proteins with multiple cellular targets. J. Pept. Sci., 2005, 11, 697-706.
56. Ginsburg, I. The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS, 2002, 110, 753-770.
57. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol., 2005, 3, 238-250.
58. Welling, M.M.; Hiemstra, P.S.; van den Barselaar, M.T.; Paulusma-Annema, A.; Nibbering, P.H.; Pauwels, E.K.J.; Calame, W. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J. Clin. Invest., 1998, 102, 1583-1590.
59. Cole, A.M.; Hong, T.; Boo, L.M.; Nguyen, T.; Zhao, C.Q.; Bristol, G.; Zack, J.A.; Waring, A.J.; Yang, O.O.; Lehrer, R.I. Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA, 2002, 99, 1813-1818.
60. Lupetti, A.; Paulusma-Annema, A.; Welling, M.M.; Senesi, S.; Van Dissel, J.T.; Nibbering, P.H. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob. Agents. Chemother., 2000, 44, 3257-3263.
61. Nibbering, P.H.; Welling, M.M.; Paulusma-Annema, A.; Brouwer, C.P.J.M.; Lupetti, A.; Pauwels, E.K.J. Tc-99m-labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus. J. Nucl. Med., 2004, 45, 321-326.
62. Sharma, S.; Verma, I.; Khuller, G.K. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob. Agents. Chemother., 2001, 45, 639-640.
63. Brouwer, C.P.J.M.; Bogaards, S.J.P.; Wulferink, M.; Velders, M.P.; Welling, M.M. Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-drug resistant) Staphylococcus aureus in mice. Peptides, 2006, 27, 2585-2591.
64. Cornish, J.; Callon, K.E.; Naot, D.; Palmano, K.P.; Banovic, T.; Bava, U.; Watson, M.; Lin, J.M.; Tong, P.C.; Chen, Q.; Chan, V.A.; Reid, H.E.; Fazzalari, N.; Baker, H.M.; Baker, E.N.; Haggarty, N.W.; Grey, A.B.; Reid, I.R. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology, 2004, 145, 4366-4374.
65. Steinstraesser, L.; Ring, A.; Bals, R.; Steinau, H.W.; Langer, S.F. The human host defense peptide LL37/hCAP accelerates angiogenesis in PEGT/ PBT biopolymers. Ann. Plast. Surg., 2006, 56, 93-98.
66. Lupetti, A.; Danesi, R.; van't Wout, J.W.; van Dissell, J.T.; Senesi, S.; Nibbering, P.H. Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin. Investig. Drugs, 2002, 11, 309-318.
67. Lupetti, A.; Paulusma-Annema, A.; Welling, M.M.; Dogterom-Ballering, H.; Brouwer, C.P.J.M.; Senesi, S.; Van Dissel, J.T.; Nibbering, P.H. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents. Chemother., 2003, 47, 262-267.
68. Peschel, A. How do bacteria resist human antimicrobial peptides? Trends Microbiol., 2002, 10, 179-186.
69. Bishop, J.L.; Finlay, B.B. Friend or foe? Antimicrobial peptides trigger pathogen virulence. Trends Mol. Med., 2006, 12, 3-6.
70. Jin, T.; Bokarewa, M.; Foster, T.; Mitchell, J.; Higgins, J.; Tarkowski, A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol., 2004, 172, 1169-1176.
71. Fritzberg, A.R.; Beaumier, P.L. Targeted proteins for diagnostic-imaging - does chemistry make a difference. J. Nucl. Med., 1992, 33, 394-397.
72. Pauwels, E.K.J.; Welling, M.M.; Feitsma, R.I.J.; Atsma, D.E.; Nieuwenhuizen, W. The labeling of proteins and ldl with tc-99m - a new direct method employing KBH4 and stannous chloride. Nucl. Med. Biol., 1993, 20, 825-833.
73. Rossin, R.; Blok, D.; Visentin, R.; Feitsma, R.I.J.; Giron, M.C.; Pauwels, E.K.J.; Mazzi, U. Tc-99m-labeling experiments on CCK4 by a direct method. Nucl. Med. Biol., 2001, 28, 865-873.
74. Welling, M.M.; Mongera, S.; Lupetti, A.; Balter, H.S.; Bonetto, V.; Mazzi, U.; Pauwels, E.K.J.; Nibbering, P.H. Radiochemical and biological characteristics of Tc-99m-UBI 29-41 for imaging of bacterial infections. Nucl. Med. Biol., 2002, 29, 413-422.
75. Welling, M.M.; Nibbering, P.H.; Paulusma-Annema, A.; Hiemstra, P.S.; Pauwels, E.K.J.; Calame, W. Imaging of bacterial infections with Tc-99m-labeled human neutrophil peptide-1. J. Nucl. Med., 1999, 40, 2073-2080.
76. Melendez-Alafort, L.; Ramirez, F.D.; Ferro-Flores, G.; de Murphy, C.A.; Pedraza-Lopez, M.; Hnatowich, D.J. Lys and Arg in UBI: A specific site for a stable Tc-99m complex? Nucl. Med. Biol., 2003, 30, 605-615.
77. Ferro-Flores, G.; Ramirez, F.D.; Melendez-Alafort, L.; de Murphy, C.A.; Pedraza-Lopez, M. Molecular recognition and stability of Tc-99m-UBI 29-41 based on experimental and semiempirical results. Appl. Radiat. Isotop., 2004, 61, 1261-1268.
78. Ferro-Flores, G.; de Murphy, C.A.; Pedraza-Lopez, M.; Melendez-Alafort, L.; Zhang, Y.M.; Rusckowski, M.; Hnatowich, D.J. In vitro and in vivo assessment of Tc-99m-UBI specificity for bacteria. Nucl. Med. Biol., 2003, 30, 597-603.
79. Decristoforo, C.; Mather, S.J. The influence of chelator on the pharmacokinetics of Tc-99m-labelled peptides. Q. J. Nucl. Med., 2002, 46, 195-205.
80. Gariepy, J.; Remy, S.; Zhang, X.G.; Ballinger, J.R.; Bolewska-Pedyczak, E.; Rauth, M.; Bisland S.K. A simple two-step approach for introducing a protected diaminedithiol chelator during solid-phase assembly of peptides. Bioconjug. Chem., 2002, 13, 679-684.
81. Babich, J.W.; Solomon, H.; Pike, M.C.; Kroon, D.; Graham, W.; Abrams, M.J.; Tompkins, R.G.; Rubin, R.H.; Fischman, A.J. Tc-99M-Labeled Hydrazino-Nicotinamide Derivatized Chemotactic Peptide Analogs for Imaging Focal Sites of Bacterial-Infection. J. Nucl. Med., 1993, 34, 1964-1974.
82. Welling, M.M.; Visentin, R.; Feitsma, H.I.J.; Lupetti, A.; Pauwels, E.K.J.; Nibbering, P.H. Infection detection in mice using Tc-99m-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41. Nucl. Med. Biol., 2004, 31, 503-509.
83. Welling, M.M.; Korsak, A.; Gorska, B.; Oliver, P.; Mikolajczak, R.; Balter, H.S.; Feitsma, H.I.J.; Pauwels, E.K.J. Kit with technetium-99m labelled antimicrobial peptide UBI 29-41 for specific infection detection. J. Labelled Comp. Radiopharm., 2005, 48, 683-691.
84. Hwang, S.W.; Lee, J.H.; Park, H.B.; Pyo, S.H.; So, J.E.; Lee, H.S.; Hong, S.S.; Kim, J.H. A simple method for the purification of an antimicrobial peptide in recombinant Escherichia coli. Mol. Biotechnol., 2001, 18, 193-198.
85. Dawson, N.F.; Craik, D.J.; McManus, A.M.; Dashper, S.G.; Reynolds, E.C.; Tregear, G.W.; Otvos, L.; Wade, J.D. Chemical synthesis, characterization and activity of RK-1, a novel alpha-defensin-related peptide. J. Pept. Sci., 2000, 6, 19-25.
86. van Berkel, P.H.C.; Welling, M.M.; Geerts, M.; van Veen, H.A.; Ravensbergen, B.; Salaheddine, M.; Pauwels, E.K.J.; Pieper, F.; Nuijens, J.H.; Nibbering, P.H. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat. Biotechnol., 2002, 20, 484-487.
87. Dekoster, H.S.; Amons, R.; Benckhuijsen, W.E.; Feijlbrief, M.; Schellekens, G.A.; Drijfhout, J.W. The use of dedicated peptide libraries permits the discovery of high-affinity binding peptides. J. Immunol. Methods, 1995, 187, 179-188.
88. Nibbering, P.H.; Ravensbergen, E.; Welling, M.M.; van Berkel, L.A.; van Berkel, P.H.C.; Pauwels, E.K.J.; Nuijens, J.H. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun., 2001, 69, 1469-1476.
89. Welling, M.M.; Brouwer, C.P.J.M.; 't Hof, W.; Veerman, E.C.I.; Amerongen, A.V.N. Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo. Antimicrob. Agents Chemother., 2007, 51, 3416-3419.
90. Lupetti, A.; Welling, M.M.; Pauwels, E.K.J.; Nibbering, P.H. Radiolabelled antimicrobial peptides for infection detection. Lancet Infect. Dis., 2003, 3, 223-229.
91. Lupetti, A.; Nibbering, P.H.; Welling, M.M.; Pauwels, E.K.J. Radiopharmaceuticals: new antimicrobial agents. Trends Biotechnol., 2003, 21, 70-73.
92. Hiemstra, P.S.; van den Barselaar, M.T.; Roest, M.; Nibbering, P.H.; van Furth, R. Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages. J. Leukocyt. Biol., 1999, 66, 423-428.
93. Sarda-Mantel, L.; Saleh-Mghir, A.; Welling, M.; Meulemans, A.; Vrigneaud, J.M.; Raguin, O.; Hervatin, F.; Martet, G.v.; Chau, F.; Lebtahi, R.; Le Guludec, D. Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections. Eur. J. Nucl. Med. Mol. I., 2007, 34, 1302-1309.
94. Melendez-Alafort, L.; Rodriguez-Cortes, J.; Ferro-Flores, G.; de Murphy, C.A.; Herrera-Rodriguez, R.; Mitsoura, E.; Martinez-Duncker, C. Biokinetics of Tc-99m-UBI 29-41 in humans. Nucl. Med. Biol., 2004, 31, 373-379.
95. Akhtar, M.S.; Qaisar, A.; Irfanullah, J.; Iqbal, J.; Khan, B.; Jehangir, M.; Nadeem, M.A.; Khan, M.A.; Afzal, M.S.; ul-Haq, I.; Imran, M.B. Antimicrobial peptide Tc-99m-ubiquicidin 29-41 as human infection-imaging agent: Clinical trial. J. Nucl. Med., 2005, 46, 567-573.
96. Vallejo, E.; Martinez, I.; Tejero, A.; Hernández, S.; Jiménez, L.; Bialostozky, D.; Sánchez, G.; Ilarraza, H.; Ferro-Flores G. Clinical utility of 99mTc-labeled ubiquicidin 29-41 antimicrobial peptide for the scintigraphic detection of mediastinitis after cardiac surgery. Arch. Med. Res., 2008, 39, 768-774.
97. Akhtar, M.; Khan, M.; Khan, B.; Irfanullah, J.; Afzal, M.; Khan, M.; Nadeem, M.; Jehangir, M.; Imran, M. An imaging analysis of 99mTc-UBI (29-41) uptake in S. aureus infected thighs of rabbits on ciprofloxacin treatment. Eur. J. Nucl. Med. Mol. I., 2008.
98. Brouwer, C.P.J.M.; Welling, M.M. Various routes of administration of 99mTc-labeled synthetic lactoferrin antimicrobial peptide hLF 1-11 enables monitoring and effective killing of multidrug-resistant Staphylococcus aureus infections in mice. Peptides, 2008, 29, 1109-1117.
99. Siaens, R.; Eijsink, V.G.H.; Dierckx, R.; Slegers, G. I-123-labeled chitinase as specific radioligand for in vivo detection of fungal infections in mice. J. Nucl. Med., 2004, 45, 1209-1216.
100. Bunyaviroch, T.; Aggarwal, A.; Oates, M.E. Optimized scintigraphic evaluation of infection and inflammation: Role of single-photon emission computed tomography/computed tomography fusion imaging. Semin. Nucl. Med., 2006, 36, 295-311.
101. Marks, C.L.; Conti, P.S. Session 4: Instrumentation and Animal Models. J. Nucl. Med. 2007, 47: 48N-50N.
102. Eckelman, W.C.; Mathis, C.A. Molecular targets. Nucl. Med. Biol., 2006, 33, 1.